H.C. Wainwright raised the firm’s price target on IceCure Medical (ICCM) to $2.50 from $2 and keeps a Buy rating on the shares after the FDA granted marketing authorization the De Novo application for ProSense cryoablation system for the local treatment of breast cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical’s ProSense® Receives FDA Approval for Breast Cancer Treatment
- Icecure Medical Ltd trading resumes
- IceCure Medical receives FDA marketing authorizationf or ProSense cryoablation
- Icecure Medical Ltd trading halted, news pending
- IceCure Medical Showcases ProSense® Success at EUSOBI Congress 2025